Marinus Pharmaceuticals, Inc. (MRNS) analyst actions
Rating and price-target actions on MRNS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the MRNS overview →
1 measured MRNS analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV | Press release | -1.34% | -2.84% |
Keep exploring
More MRNS: earnings → · SEC filings → · MRNS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) | 692 | -0.06% | 49% |
| Tyme Technologies, Inc. (TYME) | 691 | -0.28% | 41% |
| PTC Therapeutics, Inc. (PTCT) | 686 | +0.01% | 50% |
| Gilead Sciences, Inc. (GILD) | 677 | -0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.